which glp 1 drugs are approved for obesity Indications GLP-1/GIP RA Summary Sheet and Beyond! GLP-1 drug coverage for obesity
Description
The result is a market with enormous demand, high willingness to pay, and longstanding dissatisfaction
Kuhre RE, Ghiasi SM, Adriaenssens AE, et al
Policymakers should also consider the social benefits of GLP-1-RAs, such as reducing health inequities and enhancing the overall population health
A separate weight-management indication is subject to ongoing MHRA and NICE appraisal processes as of the time of writing
(PubMed) Huber H et al
